Thursday, September 24, 2009 |
| 12:00-19:30 |
Registration |
| 14:30-19:30 |
Satellite Symposium: HCV and Steatosis |
|
Session 1
Chairpersons:
|
G. Ruggiero, Italy
F. Negro, Switzerland | |
| 14:30 |
Prevalence and natural history of steatosis in HCV
L. Adinolfi, Italy |
| 14:50 |
Discussion |
| 15:00 |
Molecular mechanisms of HCV-induced steatosis
Ph. Roingeard, France |
| 15:20 |
Discussion |
| 15:30 |
Role of lipids in HCV replication
P. Andre, France |
| 15:50 |
Discussion |
| 16:00 |
HCV and insulin signaling: molecular aspects
F. Negro, Switzerland |
| 16:20 |
Discussion |
| 16:30-17:00 |
Coffee Break |
| |
Session 2
Chairpersons:
|
M. Persico, Italy
L. Adinolfi, Italy | |
| 17:00 |
The overlap between HCV and the metabolic syndrome
M. Bassendine, UK |
| 17:20 |
Discussion |
| 17:30 |
Steatosis in hepatitis C as factor of fibrogenesis
G. Svegliati-Baroni, Italy |
| 17:50 |
Discussion |
| 18:00 |
Steatosis and response to antivirals
L. Serfaty, France |
| 18:20 |
Discussion |
| 18:30-19:30 |
Panel Discussion: Challenges and recommendations for the management of steatosis in HCV |
| |
Chairpersons:
|
L. Adinolfi, Italy
F. Negro, Switzerland | |
| |
|
Friday, September 25, 2009 |
|
08:45
08:50
|
Introduction and Welcome Message
Objectives of the Conference
V. Ratziu, France |
|
09:00 |
Introductory Review Lecture: When is evidence good enough for doing more good than harm? Grading evidence on clinical trials and observational studies
N. Magrini, Italy |
| 09:20-10:50 |
Geoepidemiology of NAFLD/NASH and associated Risk Factors – The Liver Perspective |
| |
Chairpersons:
|
S. Bellentani, Italy
N. Mendez-Sanchez, Mexico | |
| |
Geoepidemiology of NAFLD/NASH and associated risk factors |
| 09:20 |
Europe
S. Bellentani, Italy |
| 09:40 |
North and South America
H. El Serag, USA |
| 10:00 |
Asia Pacific
Jian-Gao Fan, China |
| 10:20 |
Panel Discussion: Significance of Regional Differences in NAFLD/NASH epidemiology for current and future epidemic
S. Bellentani, Italy, N. Mendez-Sanchez, Mexico, and Public |
| 10:40-11:10 |
Coffee Break |
| 11:10-13:15 |
Epidemiology and Risk Factors of Secondary NAFLD/NASH |
| |
Chairpersons:
|
E. Bugianesi, Italy
T.I. Sorensen, Denmark | |
| |
Prevalence and risk factors of NAFLD/NASH in: |
| 11:10 |
Obesity
T.I. Sorensen, Denmark |
| 11:25 |
Diabetes
K. Cusi, USA |
| 11:40 |
Cardiovascular Diseases
D. Lawlor, UK |
| 11:55 |
Endocrines, diet and genetics
P. Loria, Italy |
| 12:10 |
Anti-retroviral-drugs-induced metabolic diseases in HIV infected patients
G. Guaraldi, Italy |
| 12:25 |
Wrap-up Lecture: Who should be screened for NAFLD/NASH?
A. Hadengue, Switzerland |
| 12:45 |
Panel Discussion: Challenges for the identification and screening of patients at risk for NAFLD/NASH
Panelists: E. Bugianesi, Italy, T.I. Sorensen, Denmark, and Public |
| 13:15-14:30 |
Lunch Break |
| 14:30-17:00 |
Diagnostic Tools and Strategies for NAFLD/NASH |
| |
Chairpersons:
|
A. Hadengue, Switzerland
J. George, Australia | |
| 14:30 |
How to Measure IR in Clinical Practice, Epidemiological Studies and Clinical Trials
A. Gastaldelli, Italy |
| 14:45 |
Imaging Procedures: Ultrasound, CT Scan, NMR, Proton Spectroscopy
S. Taylor-Robinson, UK |
| 15:00 |
Non-invasive Strategies for NASH and Liver Fibrosis
L. Serfaty, France
|
| 15:15 |
Liver biopsy and histology in NAFLD/NASH
P. Beradossa, France |
| 15:30 |
Limitations, pitfalls and future areas of research in histological definitions
A.D. Burt, UK |
| 15:45 |
Questions and Answer |
| 16:05 |
Wrap-Up Lecture: In Search of a Diagnostic Algorithm for the Practitioner
B. Tetri, USA |
|
16:25
17:00-17:30 |
Panel Discussion:Towards a standardization and/or simplification of diagnostic procedures
Panelists: A. Hadengue, Switzerland, J. George, Australia and Public
Coffee Break |
| 17:30-19:30 |
Natural History of NAFLD – Who Gets Cirrhosis? |
| |
Chairpersons:
|
H. Cortez-Pinto, Portugal
S. Caldwell, USA | |
| 17:30 |
Fibrosis in NASH: Risk Factors and Progression
H. Cortez-Pinto, Portugal |
| 17:45 |
Cryptogenic Cirrhosis: How Often is NASH the Real Cause?
S. Caldwell, USA
|
| 18:00 |
Hepatocellular Carcinoma and NASH
H.L. Reeves, UK |
| 18:15 |
Liver Related Morbi-Mortality in NASH
A. Sanyal, USA |
| 18:30 |
NASH: A Morbid Cofactor in Other Liver Diseases?
J. George, Australia |
| 18:45-19:30 |
Panel Discussion: Prognosis of NASH: Severe, Anedoctic or Benign?
Panelists: H. Cortez-Pinto, Portugal, S. Caldwell, USA and Public |
| 19:30 |
Conference Buffet Dinner |
| |
|
Saturday, September 26, 2009 |
| 09:00 -10:30 |
Extrahepatic Complications of Liver Fat |
| |
Chairpersons:
|
G. Marchesini, Italy
H. Yki-Jarvinen, Finland | |
| 09:00 |
Role of Liver Fat in the Pathogenesis and Progression of Insulin Resistance
H. Yki-Jarvinen, Finland |
| 09:15 |
Liver related morbidity / mortality in diabetes and other endocrine diseases
E. Bugianesi, Italy |
| 09:30 |
Liver fat / Cardiac fat, cardiac function and the cardiovascular system
G. Perseghin, Italy |
| 09:45 |
Controversy: NAFLD or NASH have/ do not have an independent role on cardiovascular morbimortality in endocrine diseases
N. Sattar, UK |
| 10:00 |
Panel Discussion: How Important is Liver Fat for the Overall Metabolic Control
Panelists: G. Marchesini, Italy, H. Yki-Jarvinen, Finland, and Public |
| 10:30-11:00 |
Coffee Break |
| 11:00-12:45 |
Pathogenesis |
| |
Chairpersons:
|
C. Day, UK
A.M. Diehl, USA | |
| 11:00 |
Mechanism(s) of steatosis: is steatosis still the “first hit”?
C. Day, UK |
| 11:20 |
Mechanism(s) of hepatocellular injury
A.M. Diehl, USA |
| 11:40 |
Mechanism(s) of hepatocellular fibrosis
F. Marra, Italy |
| 12:00 |
Panel Discussion: Implications for Translational Research
Panelists: C. Day, UK, A.M. Diehl, USA and Public |
| 12:45-14:15 |
Lunch Break |
| 14:15-18:30 |
Therapeutics |
| |
Chairpersons:
|
V. Ratziu, France
A. Sanyal, USA | |
| 14:15 |
Review Lecture: Any specific treatment for the Metabolic Syndrome
S. Del Prato, Italy
Evidenced Based Data: Focused Reviews and Recommendations |
| 14:35 |
Effect of Diet, Exercise and anti-obesity drugs on NAFLD/NASH
S. Zelber-Sagi, Israel |
| 14:55 |
Hepato-protectants and anti-oxydants in NASH
J-F. Dufour, Switzerland |
| 15:15 |
Insulin sensitizing agents and NAFLD/NASH
N. Chalasani, USA TBC |
| 15:35 |
Behavior Therapy and NAFLD/NASH
G. Marchesini, Italy |
| 15:55 |
Weight loss surgery and NAFLD/NASH
P. Mathurin, France |
| 16:15-16:45 |
Coffee Break |
| 16:45 |
Experimental Therapies in NASH
I. Leclercq, Belgium |
| 17:05 |
New Challenges: Anti-Fibrotic Therapy
M. Pinzani, Italy |
| 17:25 |
Wrap-up Lecture:
A Proposal for Current and Future Therapeutic Strategies for NASH
V. Ratziu, France |
| 17:45 |
Panel Discussion: Who to treat, how to treat 2009?
Panelists: V. Ratziu, France, A. Sanyal, USA and Public |
| 18:25-18:30 |
Concluding Remarks
S. Bellentani, Carpi (Modena), Italy, G. Marchesini, Bologna, Italy |
| |
|